"Regional Overview of Executive Summary Late-Stage Oncology Drug Pipeline Market by Size and Share The global late-stage oncology drug pipeline market size was valued at USD 10.85 billion in 2025 and is expected to reach USD 26.67 billion by 2033, at a CAGR of 11.90% during the forecast period This Late-Stage Oncology Drug Pipeline report helps you to be there on...

"API Contract Manufacturing Market Summary: According to the latest report published by Data Bridge Market Research, the API Contract Manufacturing Market  CAGR Value The Global API Contract Manufacturing Market size was valued at USD 8.1 billion in 2024 and is expected to reach USD 12.57 billion by 2032, at a CAGR of 5.87% during the forecast...

  Global Executive Summary RNA Therapeutics Market: Size, Share, and Forecast During the forecast period of 2025 to 2032 the market is likely to grow at a CAGR of 13.20%, primarily driven by the advancements in mRNA technology, increasing prevalence of chronic diseases, and rising investments in personalized medicine While preparing the first class RNA Therapeutics...

"First-in-Class Oncology Drug Market Summary: According to the latest report published by Data Bridge Market Research, the First-in-Class Oncology Drug Market The global first-in-class oncology drug market size was valued at USD 8.67 billion in 2025 and is expected to reach USD 25.08 billion by 2033, at a CAGR of14.20% during the forecast periodThe market growth is largely fueled by...

"Global Executive Summary First-in-Class Oncology Drug Market: Size, Share, and Forecast The global first-in-class oncology drug market size was valued at USD 8.67 billion in 2025 and is expected to reach USD 25.08 billion by 2033, at a CAGR of14.20% during the forecast periodThe market growth is largely fueled by rapid advancements in drug discovery technologies, high unmet medical needs...

According to a new report from Intel Market Research, the global Multi-target MET TKIs market was valued at USD 1.52 billion in 2025 and is projected to reach USD 3.18 billion by 2034, growing at a CAGR of 7.6% during the forecast period (2026–2034). This growth is propelled by the rising global incidence of non-small cell lung cancer and medullary thyroid cancer, precision oncology...

Demand Outlook for Executive Summary Hormone-Refractory Oncology Drug Market Market Size and Share CAGR Value The global hormone-refractory oncology drug market size was valued at USD 5.33 billion in 2025 and is expected to reach USD 12.46 billion by 2033, at a CAGR of 11.20% during the forecast period The wide-ranging report deals with the new business challenges and investment...

The Global In-Vivo Optical Imaging Market demonstrates robust expansion. Valued at USD 738.77 million in 2024, the market is projected to reach USD 1,772.47 million by 2032, growing at a compound annual growth rate (CAGR) of 11.56% during the forecast period of 2025 to 2032. This report analyzes market dynamics, segmentation, drivers, restraints, opportunities, and competitive...

Executive Summary RNA-Based Cancer Therapeutics Market Size and Share Across Top Segments CAGR Value The global RNA-based cancer therapeutics market size was valued at USD 415.8 million in 2025 and is expected to reach USD 947.1 million by 2033, at a CAGR of 10.80% during the forecast period   Market drivers and market restraints covered in this...

Introduction The Cell Cycle Inhibitors Market is a critical segment of the global oncology and pharmaceutical industry. Cell cycle inhibitors are targeted therapies designed to interrupt the uncontrolled division of cancer cells by blocking specific phases of the cell cycle. These drugs play a key role in modern cancer treatment, either as standalone therapies or in combination with...